UNSPSC 51141553: Denzimol

This classification denotes an anticonvulsant agent with the molecular formula C19H20N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9C78O7JATH, chemically known as 1h-imidazole-1-ethanol, alpha-(4-(2-phenylethyl)phenyl)- but generally known as denzimol, which bears US NIH Compound Identifier 53626. European Medicines Agency schedules Denzimol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06980MIG.

UNSPSC 51141553 Denzimol is a Commodity code under which state and local governments procure pharmaceutical products and related systems for public health and community health initiatives. Recent solicitations show state and local buyers acquiring naloxone (overdose-reversal medication) and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription fulfillment models to improve cost management and distribution efficiency. The code captures both emergency-response medical supplies and routine pharmaceutical procurement supporting county health departments, state health and human services agencies, and multistate cooperative purchasing alliances.

Activity under the code spans Florida, Texas, and Minnesota, with representation from county health departments, state health agencies, and regional cooperative purchasing organizations. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products available through authorized wholesalers to participating state and local government facilities including Oregon, with proposals due March 26, 2026. Cooperative purchasing vehicles dominate the landscape; MMCAP's procurement emphasizes compliance with cGMP and the Drug Supply Chain Security Act, EDI capability, and pricing flexibility through multiple net price formats.